Recent
Lisocabtagene Maraleucel for Resistant CLL: Phase I Trial Update
Avelumab Plus Axitinib Under Study in Urothelial Cancer
Tiragolumab Combination Treatment Granted Breakthrough Therapy Designation in NSCLC
Early Study of Lisocabtagene Maraleucel Plus Ibrutinib in Resistant CLL